71,500
-1.52%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ST Pharm Co
Its shares trade on KOSDAQ under the ticker 237690.KQ. It has been listed since 23 June 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩331.68bn and net income of ₩54.99bn. At that date it held total assets of ₩782.57bn and shareholders' equity of ₩593.44bn.
ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 23 Jun 2016
- Website
- stpharm.co.kr ↗
Leadership
Pay as last reported
- Mr. Jeong Seok KangChairman of the Management Board, Chief Safety Officer
- Mr. Mu Je SungChief Executive Officer, Director, since 2023
- Mr. Hyeon Min LeeManaging Director
- Mr. Sun Gi JangManaging Director
- Mr. Jun Yeong ChoiManaging Director, since 2023
- Mr. Seok Wu ChoiManaging Director
- Mr. Gyeong Yeon KimManaging Director
- Mr. Ju Seong YangManaging Director, since 2022
- Mr. Jong Won OhInternal Auditor
- Mr. Jin Seok YimAssistant Managing Director
- Mr. Jeong Yeol YoonAssistant Managing Director
- Mr. Seung Beom HanNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ST Pharm Co Ltd has a strong market presence and brand reputation in the pharmaceutical industry.
- The company has a diverse portfolio of high-quality products across multiple therapeutic areas.
- ST Pharm Co Ltd has established strategic partnerships with key suppliers and distributors, ensuring a reliable supply chain.
Weaknesses
- ST Pharm Co Ltd faces intense competition from both domestic and international pharmaceutical companies.
- The company's research and development capabilities are limited, leading to slower innovation compared to some competitors.
- ST Pharm Co Ltd has a relatively small market share in certain geographic regions, impacting its overall growth potential.
Opportunities
- The growing demand for pharmaceutical products in emerging markets presents an opportunity for ST Pharm Co Ltd to expand its sales and market reach.
- Advancements in biotechnology and personalized medicine open doors for potential collaborations and development of innovative therapies.
- The increasing focus on preventive healthcare and wellness provides an opportunity for ST Pharm Co Ltd to develop and market related products.
Threats
- Stringent government regulations and policies regarding pricing and quality control pose a threat to the profitability of ST Pharm Co Ltd.
- The possibility of patent expirations and the entry of generic competitors may impact the sales and market share of the company.
- Economic downturns and fluctuations in exchange rates can negatively affect ST Pharm Co Ltd's financial performance and international operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.